#biotech database

[chemxpert]

Japan Pharma Industry | Insights into the Paracetamol Market

The Japanese pharmaceutical industry is dominated by research and development; with swift investment in newly developed products and biotechnology. The industry has proved to be quite robust despite such constraints and the business environments involves complex regulatory mechanisms as well as pressure on the pricing of the products and services that they offer. The global market size for Japanese pharma market was assessed in 2024, approx. USD 85 billion which is expected to reach USD 90 billion in 2030. The country is quite strong with a number of MNCs, local players and emerging startup companies targeting more innovative drugs & therapeutic areas.

[clivaldatabase]

Patient safety is always a big issue of concern especially in clinical trials and during the drug development. Given the increasing speed of developing new therapies, ensuring those therapies are safe and effective prior to be made public is imperative for the preservation of patient safety and endorsement of innovative treatments. This blog post focuses on the vital role of clinical trials in improving patient safety including the procedures followed to ensure safer drug development and advancements towards making clinical trials safer.

[jcmarchi]

ApertureData Secures $8.25M Seed Funding and Launches ApertureDB Cloud to Revolutionize Multimodal AI

New Post has been published on https://thedigitalinsider.com/aperturedata-secures-8-25m-seed-funding-and-launches-aperturedb-cloud-to-revolutionize-multimodal-ai/

ApertureData Secures $8.25M Seed Funding and Launches ApertureDB Cloud to Revolutionize Multimodal AI

ApertureData, a company at the forefront of multimodal AI data management, has raised $8.25 million in an oversubscribed seed round to drive the development and expansion of its groundbreaking platform, ApertureDB. The round was led by TQ Ventures with participation from Westwave Capital, Interwoven Ventures, and a number of angel investors. The funding will allow ApertureData to scale its operations and launch its new cloud-based service, ApertureDB Cloud, a tool designed to simplify and accelerate the management of multimodal data, which includes images, videos, text, and related metadata.

Addressing the Multimodal Data Crisis

The growth of AI has led to an explosion in the generation of multimodal data across industries such as e-commerce, healthcare, retail, agriculture, and visual inspection. Despite this growth, most organizations struggle to effectively manage and utilize this data.  This inefficiency often hampers AI development, leading to longer project timelines and lower returns on investment.

ApertureData’s flagship product, ApertureDB, addresses this challenge head-on. It provides a unified database platform specifically built for managing large-scale multimodal data, which includes images, videos, documents, and their associated metadata. Unlike traditional databases focused on textual data, ApertureDB integrates graph and vector search capabilities, allowing businesses to streamline their AI workflows and significantly reduce the time spent on data preparation and management.

The Launch of ApertureDB Cloud

ApertureDB Cloud, the company’s new cloud-based platform, extends the power of ApertureDB, making it easier for enterprises to access and deploy their multimodal AI solutions without complex infrastructure setups. Users can now manage vast datasets with just a few clicks, utilizing ApertureDB Cloud’s advanced graph-vector search capabilities and seamless integration with AI applications. The platform offers a unified data layer that centralizes all relevant data types and metadata, providing fast and efficient querying and retrieval, which is crucial for AI development.

With the launch of ApertureDB Cloud, organizations can now try the platform with a risk-free 30-day trial, making it accessible for AI teams looking to streamline their data operations and scale their AI models.

A Game-Changer for AI and Machine Learning Pipelines

ApertureDB is designed to solve some of the biggest bottlenecks in AI development. By unifying multimodal data management, the platform offers several advantages, including:

35x faster dataset creation compared to traditional data integrations, speeding up AI project timelines.

63% reduction in network transfer of large visual data, improving operational efficiency.

Integrated vector similarity search and advanced graph search capabilities for complex data handling.

These features allow organizations to efficiently manage massive datasets, reducing the time spent on manual data preparation from months to just a few days. The platform is already deployed across multiple industries, from retail and e-commerce to biotechnology and generative AI startups. For instance, a major home furnishings retailer is using ApertureDB to manage product images and metadata, optimizing their recommendation systems and customer insights.

In the biotech sector, ApertureDB is helping AI-driven medical imaging and visual inspection applications, providing seamless access to large volumes of multimodal data.

Backed by Leading Investors

The $8.25 million seed round backing ApertureData was led by TQ Ventures, a New York-based venture capital firm focused on software businesses and technology-driven startups. According to Andrew Marks, General Partner at TQ Ventures, ApertureData is uniquely positioned to be a foundational player in the emerging AI landscape:

 “ApertureData has steadily built an amazing business with a wide view on the tech stack. They knew early on that traditional databases, which are geared toward textual data, would be insufficient for managing more complex multimodal data. The quantum of multimodal data and the desire to leverage it for analysis and machine learning is likely to explode over the coming decade as we are already seeing with the growth in use cases for generative and multimodal AI. And so, the work ApertureData is doing today will be foundational towards building the best infrastructure for emerging multimodal AI applications across various industries.”

TQ Ventures, founded in 2018, has a portfolio of over 80 investments and $1 billion under management, giving ApertureData access to a broad network of resources and expertise.

Also participating in the round were Westwave Capital, a pre-seed and seed-stage enterprise investor with a focus on AI, robotics, and analytics, and Interwoven Ventures, a firm specializing in early-stage investments in AI, robotics, and healthcare technology. Both investors bring significant operational experience and industry knowledge to help ApertureData scale and refine its platform for the future of multimodal AI.

Expanding Use Cases for Multimodal Data

ApertureDB’s potential spans a wide range of applications, as industries increasingly generate multimodal data and look for ways to turn this data into actionable insights. The platform’s unique ability to integrate knowledge graphs and multimodal data search functions makes it ideal for AI-driven tasks in e-commerce, agriculture, healthcare, and beyond.

For example, in smart retail, ApertureDB allows retailers to use customer data, images, and metadata to deliver personalized product recommendations and improve the customer experience. In smart agriculture, the platform helps farmers analyze images and geolocation data to optimize farming practices. Medical imaging companies leverage ApertureDB’s ability to handle large multimodal medical datasets, facilitating advanced AI-driven diagnostics.

The Road Ahead for ApertureData

With its newly secured funding, ApertureData plans to scale production deployments, enhance its platform’s user experience, and integrate more ecosystem solutions to cater to various AI and machine learning workflows. The company is also looking to expand its marketing and sales efforts, positioning itself as a leader in multimodal AI data management.

Vishakha Gupta, CEO of ApertureData, envisions a future where the demand for multimodal AI will continue to surge:

“The increasing adoption of multimodal data in powering advanced AI experiences, including multimodal chatbots and computer vision systems, has created a significant market opportunity. As more companies look to leverage multimodality, the demand for efficient management solutions like ApertureDB is expected to grow.”

Co-founded by Vishakha Gupta and Luis Remis, both former researchers at Intel Labs with deep expertise in AI and data infrastructure, ApertureData has grown quickly in response to the needs of the modern AI landscape. Their firsthand experience with managing large datasets of visual data inspired the creation of ApertureDB, a tool that is transforming how companies handle AI and machine learning pipelines.

As enterprises increasingly look to multimodal data to drive AI innovations, ApertureData is poised to lead the charge by providing the critical infrastructure needed to handle the vast, complex datasets of the future. The company’s platform is set to play a vital role in the next generation of AI innovations, helping companies turn data into competitive advantage.

[headspace-hotel]

I went down the internet rabbit hole trying to figure out wtf vegan cheese is made of and I found articles like this one speaking praises of new food tech startups creating vegan alternatives to cheese that Actually work like cheese in cooking so I was like huh that's neat and I looked up more stuff about 'precision fermentation' and. This is not good.

Basically these new biotech companies are pressuring governments to let them build a ton of new factories and pushing for governments to pay for them or to provide tax breaks and subsidies, and the factories are gonna cost hundreds of millions of dollars and require energy sources. Like, these things will have to be expensive and HUGE

I feel like I've just uncovered the tip of the "lab grown meat" iceberg. There are a bajillion of these companies (the one mentioned in the first article a $750 MILLION tech startup) that are trying to create "animal-free" animal products using biotech and want to build large factories to do it on a large scale

I'm trying to use google to find out about the energy requirements of such facilities and everything is really vague and hand-wavey about it like this article that's like "weeeeeell electricity can be produced using renewables" but it does take a lot of electricity, sugars, and human labor. Most of the claims about its sustainability appear to assume that we switch over to renewable electricity sources and/or use processes that don't fully exist yet.

I finally tracked down the source of some of the more radical claims about precision fermentation, and it comes from a think tank RethinkX that released a report claiming that the livestock industry will collapse by 2030, and be replaced by a system they're calling...

Food-as-Software, in which individual molecules engineered by scientists are uploaded to databases – molecular cookbooks that food engineers anywhere in the world can use to design products in the same way that software developers design apps.

I'm finding it hard to be excited about this for some odd reason

Where's the evidence for lower environmental impacts. That's literally what we're here for.

There will be an increase in the amount of electricity used in the new food system as the production facilities that underpin it rely on electricity to operate.

well that doesn't sound good.

This will, however, be offset by reductions in energy use elsewhere along the value chain. For example, since modern meat and dairy products will be produced in a sterile environment where the risk of contamination by pathogens is low, the need for refrigeration in storage and retail will decrease significantly.

Oh, so it will be better for the Earth because...we won't need to refrigerate. ????????

Oh Lord Jesus give me some numerical values.

Modern foods will be about 10 times more efficient than a cow at converting feed into end products because a cow needs energy via feed to maintain and build its body over time. Less feed consumed means less land required to grow it, which means less water is used and less waste is produced. The savings are dramatic – more than 10-25 times less feedstock, 10 times less water, five times less energy and 100 times less land.

There is nothing else in this report that I can find that provides evidence for a lower carbon footprint. Supposedly, an egg white protein produced through a similar process has been found to reduce environmental impacts, but mostly everything seems very speculative.

And crucially none of these estimations are taking into account the enormous cost and resource investment of constructing large factories that use this technology in the first place (existing use is mostly for pharmaceutical purposes)

It seems like there are more tech startups attempting to use this technology to create food than individual scientific papers investigating whether it's a good idea. Seriously, Google Scholar and JSTOR have almost nothing. The tech of the sort that RethinkX is describing barely exists.

Apparently Liberation Labs is planning to build the first large-scale precision fermentation facility in Richmond, Indiana come 2024 because of the presence of "a workforce experienced in manufacturing"

And I just looked up Richmond, Indiana and apparently, as of RIGHT NOW, the town is in the aftermath of a huge fire at a plastics recycling plant and is full of toxic debris containing asbestos and the air is full of toxic VOCs and hydrogen cyanide. ???????????? So that's how having a robust industrial sector is working out for them so far.

[monarch-afterdark]

Titan History: Scylla

Welcome once again to Monarch: After Dark, the digital gateway between you and the organisation dedicated to understanding and navigating this troubled new world we live in.

While our inquiry into Janos Biotech continues, we return to the regularly scheduled "Titan History" series, where we break down all you need to know about the creatures we now share our world with. For today's communication, we look to the most recent Titan crisis and examine one of the casualties; the Lovecraftian scavenger, Scylla.

(Pictured above: Scylla rampaging through Rome, prior to being confronted and executed by Godzilla, circa. 2027)

Monarch Database File: Scylla

Monarch Designation: Titanus Scylla

Height: 341 feet

Weight: 20,000 tons

Nature: Bio-Corrosive

Behavioural Classification: Destroyer

-----

A colossal cephalopod Titan that appears to have crawled out from the depths of the Cthulhu Mythos, Scylla is among one of Monarch's more recent discoveries, noted as 'Titan 024' in our database. Her discovery was recent enough that, during the construction of Monarch Outpost 55, a proper containment field for Scylla was unable to be constructed. Some of the outpost's operatives erroneously believed she was dead when they found her dormant in Arizona.

Scylla is known to us as a Titan scavenger, able to break down the carcasses of deceased Titans and convert the nutrients into a lethal waterborne bacteria. This ability led to the implementation of new protocols for Monarch's pathology teams when cleaning and disposing of Titan remains. She can also emit an incredibly dense fog-like pollutant, which she uses to feed on radiation sources or cover her while she evades an attacker, and can emit liquid nitrogen from her body. The latter ability in particular has been cited for cooling down the Antarctic ice and stabilizing global sea levels.

Scylla is also surprisingly intelligent, able to take the wreckages of ships and craft them into temporary shells for her body, and is remarkably agile in her movements, enabling her to take on opponents such as Godzilla with ease.

(Pictured above: The Moai statues of Easter Island. It is believed by Monarch these were built by the Rapa Nui people to ward off Titans like Scylla)

Like with most Titans, not much is known about Scylla's activities prior to 2019 outside of what mythological records allow. It is known that, at some point, Scylla made landfall on Easter Island. Feared by the Rapa Nui people, they erected the Moai status as megalithic scarecrows to deter her, and presumably other Titans as well.

When Scylla was awakened by Monster Zero in 2019, she erupted from beneath Monarch Outpost 55 and made her way to Arizona's capital Phoenix, where she rampaged through the city. She was pacified by the ORCA device's activation in Boston, and was among the few Titans present to witness Godzilla become the new Alpha, bowing down to him as he roared into the sky.

Between this and her next known sighting, Scylla enjoyed a deal of popularity among humanity once Monarch's record of her went public, even becoming a trending topic on social media platform Twitter once her Greek origins were confirmed.

(Pictured above: Artistic rendition of Scylla engaging the United States Coast Guard and Godzilla over possession of a nuclear warhead, circa. 2020)

Around the end of 2020, Scylla appeared off the coast of Savannah, Georgia in search of food. Her hunger led her to a discarded nuclear warhead, which she fought with the US Coast Guard for possession of. Godzilla arrived shortly after and successfully drove Scylla away after a short brawl. She then made her way to a frozen lake at the tip of South America, claiming it as her new territory. Like with all other Titans, Scylla then returned to dormancy, seemingly under Godzilla's instruction.

She did not stay dormant, however. In 2027, Scylla was lured to the Kudankulam Nuclear Power Plant in India by a reactor beacon created by Skull Island trophy hunter Raymond Martin, who (as Monarch later discovered) wanted to use her to occupy Godzilla's attention so he could proceed with his plans for Hollow Earth. After feeding on the radiation there, she would travel to other locations around the world and feed there, Godzilla always one step behind her.

Scylla attacked the United Kingdom Nuclear Labs in Preston and the Aviano Air Base in Italy, feasting off whatever she could find. Her ravenous feeding had caused her to cease cooling the planet's oceans, and Monarch instead found that she was heating the areas she attacked, causing damage to the ozone layer. After an attempted trap by Monarch failed, she was finally cornered by Godzilla in Rome and killed by a point-blank blast of his atomic breath following a short skirmish.

(Pictured above: An X-Ray scan of Scylla, part of a compiled bioacoustic database Monarch has on all Titans, circa. 2019)

-----

And there you go! While Scylla's passing means we may not be able to learn more about her, unless new data is found or another of her species emerge in the future, we do take some pride in knowing some people out there came to embrace Scylla, rather than fear her as most would.

Until next time,

Monarch: After Dark

[thecommonplacer]

Conference Preparations

✅ Registration (Few Months Ago)

✅ Poster Abstract Submission (Few Months Ago)

✅ "Help" page for the Database created by my team

✅ Poster Preparation

✅ Search for a Poster Printing shop

✅ Poster Printing

✅ Script for the Presentation

✅ Revise Undergrad Immunology Lessons

✅ Living Arrangement Confirmation

✅ Booked Airplane Tickets ✈

✅ Program Confirmation - Poster Specifications, Flow Cytometry Workshop, Registration Kit

✅ Poster Presentation Abstract Book Download

✅ Confirmation of Poster Presentation Schedule

✅ Study Profile of Speakers and Companies Partnering with the University

✅ Study The Conference Abstract Book

✅ Plan (and buy) outfits to be worn at the Conference

✅ Plan Date with My Bestie

✅ Plan Meet with former Project Member

✅ Interacted with Companies (with offices in Singapore)

✅ Saved all Points of Contacts in Address Book - for future use

❓ Restart my search for an interesting project to work on

❓ Contact Singaporean Biotech Companies

[elbiotipo]

in a long since abandoned sci-fi story of mine, the main character is fitted with a translator computer as an implant (as well as a biotech implant that allows her to breathe a limited variety of gases and liquids), but it's only languages from a certain corner of the galaxy. It can't learn adaptively, too, it would need to have a dictionary database file loaded onto it. a bit of an inch resting angle i took to kind of like. have a bit more realism (and the drama of plots where she can't understand anyone) but also have like. the easy route out in certain episodes

Oh yes, let's be honest, universal translators are very, very convenient. I also would like my characters to banter and do wordplay from day one, but without a universal translator it takes time and it does get frustrating. You have to design your story around it.

Same with adapting to other worlds, there is a lot of prep-time you have to do when going to space, imagine having to adapt to other atmospheres or biologies. This is something most sci-fi works take for granted they just play it as getting out of a plane in a different country, but it wouldn't be like that.

Still, to have an translator that STILL requires to have a database is a real interesting setup. And in fact, machine translation only gets you so far, especially with regards to dialects and everyday language.

[musickool]

What do you think about a yandere William Foster and Evan Webber?

omggg yess! yandere william foster and evan webber au ♡ ♱ · ! ꒰ ⊹ ࣪ ˖ 𑄽୧ㅤㅤ۪ㅤㅤരㅤㅤ꒱

a biotech scientist and an architect who compartmentalise between their dual identities: the facade of doting loving fathers & husbands and their dark side as sociopathic stalkers .ᐟ

prompt #1:

yandere william foster & evan webber x reader

william, as a biotech scientist & engineer, spends a lot of his time in his private lab doing research (and surveilling you). since he knows a lot about technology, you should already know where this is going...

with his infinite knowledge and wisdom, he'd come up with an idea to create some sort of spying device so he could find more information about you, to which he harvests in a gazillion folders of files on a digital database, protected by a hefty set of blockchains. he'll know your address, where you go work, mode of transport, your name, a photographic memory of your appearance, hell, even down to the nitty gritty of knowing your personal interests. this man is completely obsessed with you, loves you more than his own wife and kids. he will know everything, and you cannot stop him.

evan's your neighbour so you know his advantages are on a all-time high. he stalks you by watching you through his own home: writing notes of things you do routinely, recording you, taking pictures. on his way to work, he stalks you in his car, slowly driving by your house or as you walk into your home. he wants you, he needs you, he has to have you. to everyone, he's the friendly ol' guy who's always willing to lend a helping hand to any advances. but his intentions are far more bleaker than that....

similar to william, he too also keeps the information on a USB, as well his notebooks, storing it away somewhere unknown. he knows every single thing about you and one day, he'll lure you into his home under the false pretence of a special dinner with him as an invite, obviously knowing full well that this will be the last time you'll be seen again.

[mariacallous]

"I’m going to let him go wild on health,” former president Donald Trump said of Robert F. Kennedy Jr. at his Madison Square Garden rally in New York City this past weekend. “I’m going to let him go wild on the food. I’m going to let him go wild on the medicines.”

Kennedy, a former Democrat, suspended his presidential campaign in August and endorsed Trump. He has since launched the Make America Healthy Again campaign, an initiative focused on tackling chronic diseases that Trump has seemingly embraced in recent weeks. Given Kennedy’s anti-vaccination stance and conspiratorial leanings, some policy experts and former government officials are concerned about how his views could shape the nation’s health agenda.

Kennedy has long made false statements about the safety of vaccines and has touted disproven treatments for Covid-19, including ivermectin and hydroxychloroquine. On the campaign trail, he has railed against seed oils, blaming several chronic health conditions on their presence in processed foods.

How much influence Kennedy could have on national health policy will all depend on his role within a future Trump administration. Trump did not clarify his remarks at Sunday’s event, including what position he is considering Kennedy for. According to a CNN report that ran late Tuesday, Kennedy said Trump “promised him control of the public health agencies,” but in an email to WIRED on Wednesday, Steven Cheung, Trump’s campaign communications director, said that formal discussions of who will serve in a second Trump administration are premature.

Trump could be considering Kennedy to lead the Department of Health and Human Services, which has 80,000 federal employees, or one of the agencies within it, such as the Food and Drug Administration or the Centers for Disease Control and Prevention. It would be a departure from his previous top health picks, who had lengthy government or public health careers. For instance, Alex Azar, Trump’s HHS secretary, was deputy HHS secretary under George W. Bush and an executive at drugmaker Eli Lilly. Scott Gottlieb, a physician and investor appointed as FDA commissioner under Trump, had previously worked for the FDA and had served on the boards of pharma and biotech companies.

When asked to elaborate on Kennedy’s health priorities, Amaryllis Fox Kennedy, the former candidate’s campaign director and daughter-in-law, told WIRED: “Bobby aims to end conflicts and corruption at the agencies, ensure all testing is undertaken by scientists who have no financial interest in the outcome, and all results of all trials are released to the public. The free market will take care of it from there.” (The National Institutes of Health already requires results of clinical trials funded by the agency to be published to a government database.)

Jerome Adams, US surgeon general under Trump and current executive director of health equity initiatives at Purdue University, says that even if Kennedy were tapped to lead HHS, the FDA, or the CDC, it’s unlikely that he would ascend to one of those roles due to his lack of medical training and controversial views on public health issues. “Congressional approval is required for these positions, and his stances could be a barrier,” Adams says.

If Republicans control the Senate after next week’s election, though, that calculus could change. “The GOP has generally fallen into line in terms of supporting candidates that President Trump does,” says Genevieve Kanter, associate professor of public policy at the University of Southern California.

If chosen to be FDA commissioner, Kennedy would control the agency’s budget and priorities and could have a sizable impact by installing lower-level appointees who are sympathetic to his worldview. While the FDA commissioner does not single-handedly approve or authorize new drugs, Kantner says outside political pressure can certainly influence that process. Kennedy could also appoint members to FDA advisory committees, panels of outside experts that make recommendations to the agency on drug approvals and other regulatory matters. The FDA often follows the recommendations of advisory committees when making decisions on new drug approvals, but not always.

The FDA can also choose to not enforce some rules in certain circumstances—what’s known as enforcement discretion. Given his support for dubious and unproven therapies, such as stem cells and hyperbaric oxygen, an FDA under Kennedy, for instance, could choose to not go after companies that market unapproved treatments.

“When we think of the kind of person we want to be head of HHS or be FDA commissioner, someone ‘going wild’ isn’t exactly the first trait that comes to mind,” Kanter says. “It wouldn’t ease the public’s concern that we would see more food safety incidents and adverse events from poorly regulated drugs and devices from a lax administration that is known for embracing unscientific theories.”

Kennedy wouldn’t have free rein though. Existing laws and regulations govern how the agency works, and a new FDA commissioner wouldn’t be able to get rid of those quickly. “If you’re dealing with regulatory issues that have been long-standing and have lots of precedent, it’s just not possible to turn some of those things around or dismiss them overnight,” says a past leader of the FDA, who requested anonymity so that they could speak freely.

Likewise, even in a leadership role at HHS or the CDC, Kennedy wouldn’t be able to easily affect vaccine policy. Vaccine recommendations are made by the Advisory Committee on Immunization Practices, which comprises outside medical and public health experts. Georges Benjamin, executive director of the American Public Health Association, says Kennedy could try to stack that advisory committee with people who are sympathetic to his views on vaccination, but those members are chosen through a rigorous nomination process.

“He could certainly change policy that way, but it takes a while and it won't be a secret. There are ways in which the public can push back, including taking a case to court,” he says.

Kennendy could have influence in other ways beyond direct control of a public health agency. Trump could potentially bring Kennedy on as a White House adviser, which wouldn’t require approval by the Senate.

“Without congressional vetting and oversight, there is potential for unchecked impact. RFK's views could shape health policies, raising concerns about misinformation and harm,” Adams says.

Karoline Leavitt, national press secretary for the Trump campaign, told WIRED in an email that if reelected, Trump will establish a “special Presidential Commission of independent minds and will charge them with investigating what is causing the decades-long increase in chronic illnesses.” She did not say whether Kennedy would be chosen for that task force.

Kennedy has also been sizing himself up for another position in a potential Trump cabinet: agriculture secretary. A longtime environmental activist, Kennedy has promised to take on big farms and feedlots, reduce pesticides, and fix what he presents as a food system captured by corporate interests. “When Donald Trump gets me inside,” Kennedy said in a video shot outside the Department of Agriculture headquarters in Washington, DC, “it won’t be that way any more.”

This platform is a continuation of Kennedy’s long history as an antagonist against the agriculture industry. In 2018, Kennedy and a team of attorneys won an initial $289 million settlement against Monsanto, representing a groundskeeper who developed cancer after being soaked with a herbicide made by the agrochemical firm. He also attempted to sue the pig farming company Smithfield because of its production of hog manure, although that case was thrown out by a federal judge.

Kennedy’s past makes him an unlikely candidate for agriculture secretary, according to Daniel Glickman, who served in the role during Bill Clinton’s presidency. “It’s hard for me to imagine, given Trump’s traditional base in the heartlands, that he would pick somebody who was an advocate for breaking up large farms and breaking consolidated agriculture,” says Glickman.

Like top posts at HHS, the USDA secretary position would need to be confirmed by a Senate vote. “I don’t think [Kennedy] is a slam dunk,” says Glickman.

Trump’s pick for USDA chief during his first term was Sonny Perdue, a former governor of Georgia and founder of an agricultural trading company. Most agriculture secretaries either have a background in the industry or politics—two crucial constituencies for the person who will be in charge of a department that employs nearly 100,000 and is made up of 29 agencies, including forestry, conservation, and nutrition programs. “The difference between Sonny Perdue and Robert F. Kennedy, Jr. is like night and day,” says Glickman.

If Kennedy were to be confirmed as agriculture secretary, he might struggle to enact the most radical parts of his program. He is an outspoken critic of pesticides, but the USDA is generally not in charge of regulating those, says Dan Blaustein-Rejto, director of agriculture policy and research at the Breakthrough Institute. Rather, the EPA regulates pesticides with public health uses.

Although he may not be able to directly influence pesticide regulations, Kennedy has said he would try to “weaponize” other agencies against “chemical agriculture” by commissioning scientific research into the effects of pesticides. The USDA Agricultural Research Service has a nearly $2 billion discretionary budget for research into crops, livestocks, nutrition, food safety, and natural resources conservation.

There are other levers that an agriculture secretary could pull, says Blaustein-Rejto. The USDA is investing $3 billion through the partnership for climate-smart commodities—a scheme that’s supposed to make US agriculture more climate-friendly. A USDA chief might be able to put their thumb on their scale by influencing the selection criteria for these kinds of programs. The USDA also oversees the Commodity Credit Corporation (CCC), which has a $5 billion fund that it uses to support farm incomes and conservation programs, and to assist farmers hit by natural disasters. It’s possible that a USDA chief could influence how these CCC funds are distributed by the agency.

Kennedy has also argued that corporate interests have captured the US’s dietary guidelines, and he pledged to remove conflicts of interest from USDA groups that come up with dietary guidelines. US dietary guidelines are developed jointly by the USDA and HHS and are updated every five years, giving the agriculture secretary limited opportunities to influence any recommendations.

“If RFK is in a high-level policy role, I expect to see a lot more talk about ultra-processed foods, but I’m not sure what that would actually entail when it comes to the dietary guidelines,” says Blaustein-Rejto.

The experts WIRED spoke with largely think Kennedy’s more extreme positions will likely be constrained by bureaucracy. But the message that elevating a vocal vaccine skeptic and conspiracy theorist would send remains a serious concern ahead of a potential second Trump administration.

[amethystfairy1]

hey i had a Thought (about ttsbc) and i havent reread to check yet, so details i recalled may be wrong but

1) yknow when the institute was overhauled. the time when cub managed to delete hotguy’s info from the database. the one where a ton of people were fired and replaced. Lead Scientists, at that?

2) yknow how we suspect the Director to be alive and Directing over-city biotech institute?

is that. is that when she took over the institute. is that how she became director. who are the scientists she replaced? who were they replaced with? are the replacements hybrids and mutants in disguise? why were they replaced? only to justify the change in persons in power?

or am i perhaps reading too much into this?

(thank you for your stories! i enjoy them Very Much.❤️you are wonderful) (also thank you for the Pearl appearances. i hold them very close to my heart)

Hello hello!

I love to see all the speculation! These are all very good points, but that’s all I wanna say so I don’t give anything away one way or another 😆

But I assure you you are not reading to far into this, yes this series is mainly chacter/relationship (romantic/friendship/found family) driven, but there is an overarching narrative I’ve got planned, so keep reading between the lines if you like! And keep the thoughts coming! I absolutely love to see them!

Thank you thank you! I’m so glad you enjoyed the Pearl appearances, she’s such a darling in this series, isn’t she? Big sister mode all over the place! 🥰

[shmorp-mcdurgen]

does evelin know what's up with mandela biotech? i remember it saying somewhere she's a hacker of sorts?

After the BPS went missing, Evelin became. extremely worried. knowing the connection between MBT and some disappearances, she decided to do more research, and after being able to hack into MBT's database, she found. everything.

She found the documents on the patients and their mutations, images/videos of the procedures, plans for the future, everything. Of course, a LOT of it she couldn't stomach watching in one sitting otherwise she'd throw up, but. she watched everything, downloaded what she could, and now has the files on standby for when she gets the opportunity to release it ALL to the public.

[chemxpert]

Innovations in Pharmaceutical and Medical Device Manufacturing

Chemxpert Database offers a comprehensive look at the intersection of medical devices manufacturing and big pharmaceutical companies. By highlighting advancements in pharmaceutical research and development, Chemxpert reveals how API manufacturing companies and pharmaceutical chemicals are driving the industry forward. Furthermore, the database showcases how medical instruments companies are innovating to meet global health demands. For those seeking detailed industry insights, Chemxpert Database is an essential resource for understanding these critical sectors.

[thoughtlessarse]

Governments across Europe – including Ireland – are being charged up to 20 times what it costs to produce a ‘miracle’ drug for cystic fibrosis. The production cost of the drug Kaftrio could be as low as just €5,200 per patient per year and be profitable, a team of British scientists has calculated; yet governments are being charged an estimated €70,000 to over €100,000 for these and similar medicines by the US biotech firm Vertex Pharmaceuticals. That is according to a new analysis by Investigate Europe who examined Vertex’s accounts to discover its revenues in a number of European countries as well as costs to governments. Game-changing medicines to treat cystic fibrosis (CF) known as CFTR modulators have been approved in the EU since 2012. Four are now on the market, including the more recent ‘miracle’ Kaftrio and Kalydeco therapies. Ireland was among the first in Europe to get access to Kaftrio in 2020 due to a drug pipeline deal agreed with Vertex in 2017. Benefits can reportedly include a 10% to 14% rise in lung function as well as reduced need for hospitalisation due to chest infections. Dr Andrew Hill, a British researcher and adviser to the World Health Organisation (WHO), monitors shipments of Vertex’s raw ingredients on import-export databases. Tracking their value, his team calculated that Kaftrio could be produced for just $5,600 (€5,200) per patient per year and would still be profitable. The team of scientists estimated the generic cost of producing Kaftrio in India, where active ingredients of the drug are already produced. A profit margin of 10% and an average Indian tax of 27% were built into the calculations. Hill told Investigate Europe: “But Vertex has a monopoly so the choice for a country is either you buy this drug at the Vertex price, or you get nothing.” Vertex, however, challenged the methodology used, saying that the production costs quoted in this article are inaccurate. In addition they claim that “the price of these medicines is not determined by the production costs, but by the investment made in their development, the risk undertaken, and their value to patients and the health care system”, a spokesperson said. They added:

continue reading

US drug pricing coming to an EU member near you. Oops, sorry, it's already here.

[jcmarchi]

New model identifies drugs that shouldn’t be taken together

New Post has been published on https://thedigitalinsider.com/new-model-identifies-drugs-that-shouldnt-be-taken-together/

New model identifies drugs that shouldn’t be taken together

Any drug that is taken orally must pass through the lining of the digestive tract. Transporter proteins found on cells that line the GI tract help with this process, but for many drugs, it’s unknown which of those transporters they use to exit the digestive tract.

Identifying the transporters used by specific drugs could help to improve patient treatment because if two drugs rely on the same transporter, they can interfere with each other and should not be prescribed together.

Researchers at MIT, Brigham and Women’s Hospital, and Duke University have now developed a multipronged strategy to identify the transporters used by different drugs. Their approach, which makes use of both tissue models and machine-learning algorithms, has already revealed that a commonly prescribed antibiotic and a blood thinner can interfere with each other.

“One of the challenges in modeling absorption is that drugs are subject to different transporters. This study is all about how we can model those interactions, which could help us make drugs safer and more efficacious, and predict potential toxicities that may have been difficult to predict until now,” says Giovanni Traverso, an associate professor of mechanical engineering at MIT, a gastroenterologist at Brigham and Women’s Hospital, and the senior author of the study.

Learning more about which transporters help drugs pass through the digestive tract could also help drug developers improve the absorbability of new drugs by adding excipients that enhance their interactions with transporters.

Former MIT postdocs Yunhua Shi and Daniel Reker are the lead authors of the study, which appears today in Nature Biomedical Engineering.

Drug transport

Previous studies have identified several transporters in the GI tract that help drugs pass through the intestinal lining. Three of the most commonly used, which were the focus of the new study, are BCRP, MRP2, and PgP.

For this study, Traverso and his colleagues adapted a tissue model they had developed in 2020 to measure a given drug’s absorbability. This experimental setup, based on pig intestinal tissue grown in the laboratory, can be used to systematically expose tissue to different drug formulations and measure how well they are absorbed.

To study the role of individual transporters within the tissue, the researchers used short strands of RNA called siRNA to knock down the expression of each transporter. In each section of tissue, they knocked down different combinations of transporters, which enabled them to study how each transporter interacts with many different drugs.

“There are a few roads that drugs can take through tissue, but you don’t know which road. We can close the roads separately to figure out, if we close this road, does the drug still go through? If the answer is yes, then it’s not using that road,” Traverso says.

The researchers tested 23 commonly used drugs using this system, allowing them to identify transporters used by each of those drugs. Then, they trained a machine-learning model on that data, as well as data from several drug databases. The model learned to make predictions of which drugs would interact with which transporters, based on similarities between the chemical structures of the drugs.

Using this model, the researchers analyzed a new set of 28 currently used drugs, as well as 1,595 experimental drugs. This screen yielded nearly 2 million predictions of potential drug interactions. Among them was the prediction that doxycycline, an antibiotic, could interact with warfarin, a commonly prescribed blood-thinner. Doxycycline was also predicted to interact with digoxin, which is used to treat heart failure, levetiracetam, an antiseizure medication, and tacrolimus, an immunosuppressant.

Identifying interactions

To test those predictions, the researchers looked at data from about 50 patients who had been taking one of those three drugs when they were prescribed doxycycline. This data, which came from a patient database at Massachusetts General Hospital and Brigham and Women’s Hospital, showed that when doxycycline was given to patients already taking warfarin, the level of warfarin in the patients’ bloodstream went up, then went back down again after they stopped taking doxycycline.

That data also confirmed the model’s predictions that the absorption of doxycycline is affected by digoxin, levetiracetam, and tacrolimus. Only one of those drugs, tacrolimus, had been previously suspected to interact with doxycycline.

“These are drugs that are commonly used, and we are the first to predict this interaction using this accelerated in silico and in vitro model,” Traverso says. “This kind of approach gives you the ability to understand the potential safety implications of giving these drugs together.”

In addition to identifying potential interactions between drugs that are already in use, this approach could also be applied to drugs now in development. Using this technology, drug developers could tune the formulation of new drug molecules to prevent interactions with other drugs or improve their absorbability. Vivtex, a biotech company co-founded in 2018 by former MIT postdoc Thomas von Erlach, MIT Institute Professor Robert Langer, and Traverso to develop new oral drug delivery systems, is now pursuing that kind of drug-tuning.

The research was funded, in part, by the U.S. National Institutes of Health, the Department of Mechanical Engineering at MIT, and the Division of Gastroenterology at Brigham and Women’s Hospital.

Other authors of the paper include Langer, von Erlach, James Byrne, Ameya Kirtane, Kaitlyn Hess Jimenez, Zhuyi Wang, Natsuda Navamajiti, Cameron Young, Zachary Fralish, Zilu Zhang, Aaron Lopes, Vance Soares, Jacob Wainer, and Lei Miao.

[luv-assangiebatch]

So it starts....

I started my PrecisionMed!AU fic...we'll see how long I can go. I am also still trying to think of a title...

Julian was an intriguing man with a complicated and somewhat dangerous past.  A computer hacking genius in his teens led into a life of activism and journalism throughout his twenties and thirties.  He seemed invincible and fearless as he took on large corporations and dared to challenge national government institutions.  The website he created from his determination and brilliance allowed anonymous sources to share inside information showcasing the sins of some of the most powerful and influential people in the world.

In his never-ending quest for transparency and truth, Julian one day found himself in the crosshairs of the United States after one of their own military officers sent him an entire database of US confidential information.  Aware he was constantly tracked by the CIA and other government spies, he maintained his courage and determination in the face of such adversity.  His small team of volunteers partnered with major mainstream media outlets to expose the deepest, darkest secrets of the US which would create shockwaves for years to come.

Always so stubbornly fearless, Julian ignored the danger that constantly followed him.  He felt exposing these scandalous secrets was the best way to ensure a proper work of checks and balances for all societies across the globe.  He was clever, creative, elusive, and mysterious.  He believed he could outsmart anyone, and as his website and organization grew into a conglomerate of volunteers with unique and special talents, they all helped to protect Julian at all costs.  However, a day finally came when his most trusted colleagues helped him evade capture and incarceration, and they knew it was not safe for him to continue on this path.

Ever so headstrong, Julian did not want to back down.  This organization was his vision, the culmination of his blood, sweat, and broken sanity for over half of his life.  However, as danger continued to close in, his advisors were finally able to convince him that he needed to disappear, at least for a while, and they would continue to maintain his mission.  Julian was the face of the organization, and a very unique one at that.  He was statuesque with an ethereal, tousled, platinum blonde mane whose locks ran down the length of his slender, chiseled face.  He had deep, dark zircon eyes that shined when the light hit them just right, once they peeked out from behind the strands of hair that tended to hang over the right side of his face.  A striking man indeed, who had his share of female fans who were drawn in by his beauty and conviction.  However, it was his unique beauty that put him in danger and why his colleagues urged him to disappear for a while to save not only the mission but possibly his life.

Julian was a stubborn and prideful man.  He was no stranger to donning a disguise every now and then to avoid detection, but he refused to change himself or his look for good.  Always clever and with the help of his trusted colleagues, his hacker abilities gave way to erasing him from existence in the digital world, which in this day and age was just as good as burning a body.

Julian ended up retreating to Basel, Switzerland which was a fairly low profile corner of the political world.  A great hiding place for a political refugee such as himself.  Donations from his organization helped to get him settled, but he knew he needed to cut as many ties as possible to protect himself and his mission.  Basel was known for having a prominent biotech presence and soon enough with his doctorate and expertise in computer programming, Julian was able to land a job at a tumor profiling company as their new VP of Therapeutic Bioinformatics. While this shift in home and career was facilitated to protect himself and his original mission, he never expected to become fully immersed in it and find a whole new life—nor did he anticipate meeting her.

[monarch-afterdark]

Superspecies History: Snarehunter

Welcome once again to Monarch: After Dark, the digital gateway between you and the organisation dedicated to understanding and navigating this troubled new world we live in.

We approach the finish line further and further, presenting a creature that had eluded the eyes of Monarch for many years before finally showing itself as part of a deadly plot, the Snarehunter.

(Pictured above: Artistic depiction of a Snarehunter Valkyrie carrying off a deer)

Monarch Database File: Snarehunter

Monarch Designation: Cantus formica (Snarehunter castes), Cantus silva ant (Snarehunter Queen)

Length: 1-3 feet (smaller castes), 130 feet (Snarehunter Queen)

Castes: Forager, Builder, Guardian, Valkyrie, Queen

Species Designation: Insectoid superspecies (Snarehunter castes), Insectoid florafauna (Snarehunter Queen)

Behavioural Classification: Protector (Snarehunter Queen)

-----

Monarch first learned of the Snarehunters from a casual remark by stranded WW2 pilot Hank Marlow. Whilst left alone with Monarch operatives Houston Brooks and Lin San, Marlow heard the sound of birds chirping and commented that it was actually an ant making the sounds. To quote him directly; "sounds like a bird, but it's a fucking ant". Thankfully for them, no Snarehunters appeared to menace them and Marlow's remark was left as such.

First discovered in the flesh by Monarch in 2015, Snarehunters were shown to exhibit a complex social structure between the five known castes, not too dissimilar to modern ant species. The Foragers collect resources for the colony, Builders create their hills, Guardians protect the colony from attackers and Valkyries go out hunting.

The Queen, growing to sizes rivalling smaller Titans, is rarely seen above ground and is almost entirely focused on reproduction to keep the colony's numbers strong. Queens will only emerge if their colony is under serious threat or destroyed outright.

Typically a passive species, the Snarehunters first encountered by Monarch were driven into a frenzied state by a biological pathogen created by Janos Biotech, which had infected a colony once it made its way to the island.

(Pictured above: Artistic rendition of Kong battling an infected Snarehunter Queen, circa. 2015)

In 2015, during a mission to Skull Island to investigate the mysterious Janos Biotech, a Monarch expedition team uncovered bioweapon experiments the organisation was conducting on a hijacked vessel stationed in the island's waters. After seeing what the bioweapon could do to Skull Island's fauna, Monarch uncovered that the fungus had gotten onto the island itself and infected a colony of Snarehunters, driving them into a frenzy.

Meeting with Houston Brooks and his son Aaron near Monarch Outpost 33, the Monarch team quickly got to work creating an antidote, planning to administer it to the Snarehunter Queen, so she wouldn't produce an infected colony and overrun the island. Assisting Kong in his battle with the infected Queen, Monarch were successfully able to administer the antidote. Though Kong ultimately killed the Queen anyway, the antidote was administered to other infected Snarehunters, ensuring the colony would survive.

It is unknown if the Snarehunter colony, or any others, survived the ravaging of the island in 2021. While others may persist in Hollow Earth, this has yet to be confirmed.

-----

And that's all she wrote for the Snarehunter! While we remain hopeful that the Snarehunters are among the surviving species on a post-2021 Skull Island (after all, surely not all of the bird calls we hear are birds, right?), we cannot be certain as of right now.

Until next time,

Monarch: After Dark